Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Gains from Investment Securities (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Gains from Investment Securities for 12 consecutive years, with -$5000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 100.01% year-over-year to -$5000.0, compared with a TTM value of -$5000.0 through Dec 2025, down 100.01%, and an annual FY2025 reading of -$5000.0, down 100.01% over the prior year.
  • Gains from Investment Securities was -$5000.0 for Q4 2025 at Agios Pharmaceuticals, down from -$2000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $43.0 million in Q4 2024 and bottomed at -$6.2 million in Q3 2021.
  • Average Gains from Investment Securities over 5 years is $2.8 million, with a median of $20500.0 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities crashed 3640.36% in 2021, then surged 13946.41% in 2024.
  • Year by year, Gains from Investment Securities stood at $520000.0 in 2021, then crashed by 30.77% to $360000.0 in 2022, then decreased by 15.0% to $306000.0 in 2023, then soared by 13946.41% to $43.0 million in 2024, then tumbled by 100.01% to -$5000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for AGIO at -$5000.0 in Q4 2025, -$2000.0 in Q3 2025, and $2000.0 in Q1 2025.